Studies: Spending on Accelerated Approval Drugs Is Growing Fast

  • Dec 09, 2021

    The FDA’s accelerated approval pathway for experimental therapies has been criticized by practitioners and health insurers in recent months following the controversial approval of Alzheimer’s drug Aduhelm (aducanumab). Aduhelm is just the latest of many experimental therapies that has been approved with limited clinical evidence of efficacy — and payers and independent researchers say the FDA should revamp the process to contain costs. Read more
    © 2024 MMIT
  • Peter Johnson

    Peter has worked as a journalist since 2011 and has covered health care since 2020. At AIS Health, Peter covers trends in finance, business and policy that affect the health insurance and pharma sectors. For Health Plan Weekly, he covers all aspects of the U.S. health insurance sector, including employer-sponsored insurance, Medicaid managed care, Medicare Advantage and the Affordable Care Act individual marketplaces. In Radar on Drug Benefits, Peter covers the operations of (and conflicts between) pharmacy benefit managers and pharmaceutical manufacturers, with a particular focus on pricing dynamics and market access. Before joining AIS Health, Peter covered transportation, public safety and local government for various outlets in Seattle, his hometown and current place of residence. He graduated with a B.A. from Colby College.

The Latest
Meet Our Reporters

Meet Our Reporters

×
×